United States Patent 8,431,597 Scope, Claims, and US Patent Landscape Analysis
A pharmaceutical-composition claim of US Patent 8,431,597 covers a broad “composition of matter” framework: a drug substance (or salt) plus a conventional, pharmaceutically acceptable carrier or excipient. On its face, claim 1 reads as a generic structure that can sweep across multiple oral or parenteral formulations unless the specification limits the covered compound, salt forms, and carrier/excipient types.
What does US Patent 8,431,597 claim in the US, and how broad is it?
Bottom line: Claim 1 is a wide, platform-style composition claim that generally does not limit dosage form, route of administration, concentration, release profile, or specific excipient identities. Its practical scope therefore depends on what the “compound” is (defined in the patent’s specification and claim dependencies) and on whether other claims narrow the coverage.
Is claim 1 limited by dosage form, route, or excipient identity?
Claim 1 language provided:
“1. A pharmaceutical composition, comprising a compound which is or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.”
From this wording alone, claim 1 is not explicitly restricted to:
- tablets vs. capsules vs. solutions vs. suspensions vs. injectables
- oral vs. parenteral vs. transdermal administration
- immediate-release vs. modified-release
- specific polymers, binders, disintegrants, solvents, surfactants, or buffers
The breadth can be constrained only if:
- the “compound” is defined in the specification and the claims (directly or indirectly) to a particular chemical structure or salt family, and/or
- dependent claims add limitations (dosage, excipients, manufacturing, particle size, polymorphs, etc.), and/or
- prosecution history estops broader interpretation (not provided here).
What controls infringement risk for a generic formulation?
Generic entry risk for claim 1 turns on two claim-construction anchors:
- Does the accused product contain the same “compound” (or a “pharmaceutically acceptable salt thereof”) as defined by the patent?
- Is the formulation a “pharmaceutical composition” with a “pharmaceutically acceptable carrier or excipient” (virtually all commercial drug products meet this)?
If the “compound” is narrow (a single active ingredient or specific salt family), then claim 1 behaves like a broad formulation-covering claim on top of a specific API. If the “compound” definition is broad across a class of structures, claim 1 may function as an umbrella covering numerous APIs or salts in that class.
Does claim 1 cover both the free base and salts?
Yes. The claim covers:
- the “compound”
- “a pharmaceutically acceptable salt thereof”
This extends coverage to both polymorphic and salt-form implementation strategies, unless limited by specification or dependent claims.
How many claims matter, and which other claim types likely narrow coverage beyond claim 1?
Bottom line: You supplied only claim 1’s language. In most US composition patents, the broad independent composition claim is paired with dependent claims that restrict the scope. The presence or absence of dependent claims is decisive for formulation-level protection.
What dependent-claim categories typically narrow composition claims?
Common narrowing claim types include:
- specific salt forms (e.g., hydrochloride, mesylate, besylate, sulfate)
- specific dosage forms (capsule, tablet, injectable solution)
- specific excipient lists or functional classes (buffers, polymers, surfactants)
- particle size ranges, polymorphs, hydrates/solvates
- dissolution profiles, sustained release matrices
- manufacturing method claims (granulation, lyophilization, spray-drying)
With only claim 1 provided, the enforceable practical perimeter cannot be fully mapped.
What patents protect the same “compound” class as US 8,431,597 in the US?
Bottom line: The relevant patent landscape depends on the identity of the “compound.” A US composition claim of this type typically clusters into:
- initial discovery patents (compound synthesis and intermediates)
- later salt patents (salt forms and preparation)
- formulation patents (excipients, dosage forms, release systems)
- method-of-use patents (therapeutic indications)
- regulatory exclusivity overlays (New Chemical Entity exclusivity, pediatric exclusivity)
Because the active “compound” is not specified in the prompt, a complete US landscape cannot be generated without the compound identity, even though US patents generally maintain families around the same API and salt forms.
When does US 8,431,597 lose exclusivity based on patent term mechanics?
Bottom line: Patent-term expiration for US utility patents is computed from the earliest effective non-provisional filing date (20-year term, with adjustments). A determination requires the patent’s filing history, claims priority, and any Patent Term Adjustment (PTA) or Patent Term Extension (PTE).
Without the publication data, priority dates, and PTA/PTE values for US 8,431,597, a concrete expiration date cannot be stated.
Is US 8,431,597 still enforceable given potential terminal disclaimers, obviousness-type double patenting, or reexamination?
Bottom line: Enforceability can be undermined by:
- terminal disclaimers that cap life to an earlier family member
- OB-DP conflicts between continuations/divisionals
- reexamination or post-grant review invalidation
- failure to pay maintenance fees (if applicable)
A correct status check requires the patent’s prosecution and post-grant record, which is not provided.
What is the Orange Book status of the drugs covered by US 8,431,597?
Bottom line: Orange Book listing is driven by a specific FDA application and active ingredient (plus dosage form/strength and listed patents with expiration). Without the covered active ingredient and the relevant NDA/ANDA/BLA, Orange Book status cannot be mapped.
What formulation design-arounds are plausible against claim 1?
Bottom line: Claim 1 is a broad composition framework. Design-arounds focus less on excipient selection (because “pharmaceutically acceptable carrier or excipient” is generic) and more on avoiding inclusion of the claimed compound/salt, or avoiding infringement by channeling into non-salt forms not covered by the “pharmaceutically acceptable salt thereof” interpretation.
Most plausible design-around levers
- Use a different salt form not encompassed by the patent’s defined “pharmaceutically acceptable salt” scope (if the specification limits it).
- Use a different compound (different stereoisomer, free base vs. salt, or different chemical structure within an otherwise broad “compound” definition).
- Use an alternative delivery system only helps if dependent claims recite dosage forms or release profiles. Claim 1 alone is not limited to delivery system mechanics.
- Avoid the claimed excipient combination only helps if dependent claims specify excipients or excipient classes. Claim 1 alone does not.
Litigation pattern against “composition + carrier/excipient” claims
When claim 1 is that broad, challengers typically attack:
- claim construction (“compound” scope)
- written description and enablement for the breadth of salts/formulations
- indefiniteness or overbreadth relative to the disclosed examples (depending on specification)
- obviousness/nonobviousness for broad composition coverage
Actual outcomes depend on the specification and dependent claims.
How does claim 1 compare with typical composition patents in the same class?
Bottom line: Claim 1 matches a common template for formulation patents that piggyback on an API discovery patent. Its novelty is usually argued on the identity of the “compound” rather than on carrier selection. Competitive advantage, when present, comes from:
- maintaining the API as protected matter while also protecting formulation embodiments through dependent claims or later continuations.
What generic entry risks exist for products that contain the same compound?
Bottom line: If a generic contains the same claimed compound (or a covered salt) in any pharmaceutical composition with typical pharmaceutically acceptable excipients, claim 1 creates infringement exposure unless:
- the generic avoids the specific salt(s) or compound defined in the patent, or
- the patent is invalidated or no longer enforceable, or
- a court construes “compound” narrowly based on the specification.
In practice, generic risk often focuses on whether the patent is listed in the Orange Book against the relevant NDA/ANDA.
What patent estate strength conclusions can be drawn from claim 1 alone?
Bottom line: Claim 1 alone suggests:
- high potential breadth at the formulation layer
- low value in distinguishing between different dosage forms unless dependent claims narrow it
- enforceability and real-world strength likely depend on the underlying API definition and the rest of the claim set
A robust estate usually includes at least one of:
- compound/salt claims (core protection)
- formulation-dependent claims (specific excipients/dosage forms)
- method-of-use claims (indication-specific protection)
Without the identity of the “compound” and without claim set details beyond claim 1, estate strength cannot be fully characterized.
Key Takeaways
- US 8,431,597 claim 1 is a broad composition claim covering “compound (or pharmaceutically acceptable salt)” plus “pharmaceutically acceptable carrier or excipient.”
- Claim 1 does not, by its face, limit dosage form, route, release profile, or excipient identity; practical scope depends on how the “compound” is defined in the specification and on dependent claim limitations.
- Design-around leverage most often comes from changing the compound or salt form, or from escaping limitations present in dependent claims (not claim 1).
- A complete US patent landscape (other family patents, Orange Book listings, expiration/term, litigation) cannot be mapped without the identity of the “compound” and the patent’s bibliographic/prosecution data.
FAQs
-
Does a claim that only requires “pharmaceutically acceptable carrier or excipient” cover standard commercial formulations?
Usually it sweeps broadly; infringement hinges on whether the accused product contains the claimed compound (or covered salt) and whether dependent claims or construction narrow the carrier/excipient scope.
-
Can a generic avoid infringement by choosing a different salt form?
It can if the patent’s salt coverage is constrained by specification/definitions or dependent claims; otherwise “pharmaceutically acceptable salt thereof” can be hard to design around.
-
How do dependent claims typically change the scope of a broad composition claim like this?
Dependent claims often introduce specific salt identities, dosage forms, excipient lists, or release/dissolution parameters that meaningfully narrow coverage.
-
What matters more for Paragraph IV risk: composition patents or API patents?
Both can matter, but for a composition claim like claim 1, the key is whether the generic uses the same claimed API/salt that is listed against the relevant FDA application.
-
How is expiration calculated for US composition patents like 8,431,597?
From the earliest effective non-provisional filing date plus PTA, subject to terminal disclaimers and any patent term adjustments/extensions tied to regulatory approvals.
References (APA)
- United States Patent and Trademark Office (USPTO). Patent 8,431,597.
